Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

3D illustration of BEVACIZUMAB title on a medical document
The EMA is reviewing a marketing application for an ophthalmic formulation of bevacizumab • Source: Alamy

The marketing authorization application (MAA) for what could be the first ophthalmic formulation of bevacizumab to win regulatory approval in the EU has reached the later stages of the European Medicines Agency’s review process.

The EMA’s human medicines committee, the CHMP, was due to adopt a list of outstanding issues it has regarding the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards